A calcium spot on a mammogram usually means a healthy breast. But new research shows this sign might warn about heart trouble instead. A massive review looked at data from about 30,000 women over six to 12 years. They found that breast arterial calcification, or BAC, was linked to significantly higher chances of having a heart event. The risk was nearly double for those with this calcium buildup. This finding matters because mammograms are already done for breast checks. Seeing calcium there could help doctors spot heart danger earlier in women who often get missed by standard tests. The study also showed a very strong link between this calcium and actual coronary artery disease. This means the calcium is not just a random mark but a sign of underlying heart blockage. While the review combined many smaller studies, the signal was clear and consistent across the data. No safety issues were reported because this is a sign seen on an image, not a treatment. This simple marker could become a powerful tool to protect women's hearts without adding extra cost or time to their routine care.
Breast arterial calcification on mammography predicts higher cardiovascular event risk in womenCalcium on mammograms signals higher heart risk for women
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This systematic review and meta-analysis examined the association between breast arterial calcification (BAC) on mammography and cardiovascular outcomes in women. The analysis included approximately 25,000 women from cohort studies and approximately 5,000 women from OR-based analyses. Follow-up duration ranged from 6 to 12 years.
The primary outcome was incident cardiovascular events. BAC was associated with significantly higher incident cardiovascular events, with a pooled HR of 1.82 (95% CI 1.37 to 2.43; p <0.001). The analysis also assessed coronary artery disease (CAD) and coronary artery calcium (CAC) as secondary outcomes.
BAC was strongly associated with underlying coronary pathology, with a pooled adjusted OR of 4.00 (95% CI 2.44 to 6.56). Similarly elevated odds were observed for CAC, though specific effect sizes were not reported for this secondary outcome. The authors note that adverse events, discontinuations, and tolerability were not reported.
The study supports the potential role of BAC as a scalable, no-added-cost marker to enhance cardiovascular risk assessment in women. However, causality was not reported, and the setting was not reported.